Clinuvel Pharmaceuticals Ltd
CUVL
Analytical Summary
Clinuvel Pharmaceuticals Ltd shows strong fundamentals with top-quartile Profit Margin (%) and Operating Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.
4-Year Financial Trajectory
AnnualBullish Indicators
- Operating Margin (%)Operating Margin (%) is in the top quartile
- Profit Margin (%)Profit Margin (%) is in the top quartile
Bearish Risks
- No bearish risks detected.
Health Breakdown
Statement lens
Choose the reporting cadence, isolate a period range, or search directly for a metric.
| Metric | FY 2026 Jun 30, 2026 20-F ↗ | FY 2025 Jun 30, 2025 20-F ↗ | FY 2024 Jun 30, 2024 20-F ↗ | FY 2023 Jun 30, 2023 20-F ↗ |
|---|---|---|---|---|
| Revenue Growth YoY (%) |
5.2%
Fair
Fair
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
At sector avg
|
5.5%
Fair
Fair
Year-over-year change in total revenue
Optimal:
> 10%
vs Sector:
Above avg (+11%)
|
— | — |
| EPS Growth YoY (%) |
0.0%
Caution
Caution
Year-over-year change in earnings per share
Optimal:
> 10%
|
-2.1%
Weak
Weak
Year-over-year change in earnings per share
Optimal:
> 10%
|
— | — |
| Net Income Growth YoY (%) |
0.2%
Caution
Caution
Year-over-year change in net income |
-1.0%
Weak
Weak
Year-over-year change in net income |
— | — |
| FCF Growth YoY (%) |
-56.2%
Weak
Weak
Year-over-year change in free cash flow |
34.2%
Excellent
Excellent
Year-over-year change in free cash flow |
— | — |
| Metric | FY 2026 Jun 30, 2026 20-F ↗ | FY 2025 Jun 30, 2025 20-F ↗ | FY 2024 Jun 30, 2024 20-F ↗ | FY 2023 Jun 30, 2023 20-F ↗ |
|---|---|---|---|---|
| Operating Margin (%) (%) |
43.4%
Excellent
↓
Excellent
Declining
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Above avg (+262%)
|
43.4%
Excellent
Excellent
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Above avg (+262%)
|
49.3%
Excellent
Excellent
Operating income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Above avg (+311%)
|
— |
| Effective Tax Rate (%) (%) |
29.2%
Caution
→
Caution
Stable
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
30.1%
Weak
Weak
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
29.7%
Caution
Caution
Actual taxes paid relative to pre-tax income
Optimal:
15-25%
|
— |
| Profit Margin (%) (%) |
36.0%
Excellent
↓
Excellent
Declining
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Above avg (+350%)
|
37.8%
Excellent
Excellent
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Above avg (+373%)
|
40.3%
Excellent
Excellent
Net income as a percentage of revenue
Optimal:
> 15%
vs Sector:
Above avg (+404%)
|
— |
| FCF Margin (%) (%) |
18.4%
Good
↓
Good
Declining
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
44.3%
Excellent
Excellent
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
34.7%
Excellent
Excellent
Free cash flow as a percentage of revenue
Optimal:
> 10%
|
— |
| FCF / Net Income (x) |
0.51x
Weak
↓
Weak
Declining
Free cash flow relative to reported net income
Optimal:
> 1x
|
1.17x
Fair
Fair
Free cash flow relative to reported net income
Optimal:
> 1x
|
0.86x
Caution
Caution
Free cash flow relative to reported net income
Optimal:
> 1x
|
— |
| Metric | FY 2026 Jun 30, 2026 20-F ↗ | FY 2025 Jun 30, 2025 20-F ↗ | FY 2024 Jun 30, 2024 20-F ↗ | FY 2023 Jun 30, 2023 20-F ↗ |
|---|---|---|---|---|
| Return on Invested Capital (%) |
10.5%
Good
↓
Good
Declining
Return earned on debt + equity capital invested
Optimal:
> 10%
|
11.8%
Good
Good
Return earned on debt + equity capital invested
Optimal:
> 10%
|
14.8%
Good
Good
Return earned on debt + equity capital invested
Optimal:
> 10%
|
— |
| Return on Capital (%) (%) |
13.7%
Good
Good
Operating profit relative to total assets
Optimal:
> 10%
|
15.0%
Excellent
Excellent
Operating profit relative to total assets
Optimal:
> 10%
|
— | — |
| Return on Common Equity (%) (%) |
12.3%
Fair
↓
Fair
Declining
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Below avg (-18%)
|
14.8%
Fair
Fair
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
At sector avg
|
17.3%
Good
Good
Profit generated per dollar of shareholder equity
Optimal:
> 15%
vs Sector:
Above avg (+15%)
|
— |
| Metric | FY 2026 Jun 30, 2026 20-F ↗ | FY 2025 Jun 30, 2025 20-F ↗ | FY 2024 Jun 30, 2024 20-F ↗ | FY 2023 Jun 30, 2023 20-F ↗ |
|---|---|---|---|---|
| Sales/Revenue/Turnover (USD) | $64.32M | $61.12M | $57.91M | — |
| Depreciation Expense (USD) | $390.35K | $508.88K | $493.71K | — |
| Net Income, GAAP (USD) | $23.18M | $23.12M | $23.35M | — |
| Operating Cash Flow (USD) | $12.91M | $27.30M | $23.75M | — |
Secondary lens
Benchmark Lens
Compare CUVL against peers after checking the statement evidence.
Open lens
Benchmark Lens
Compare CUVL against peers after checking the statement evidence.
Signals
Key bullish and bearish indicators for CUVL
Operating Margin (%) is in the top quartile
Profit Margin (%) is in the top quartile
No bearish signals detected
Percentile Rankings
How CUVL compares to all companies
Compare CUVL with peers
Stack CUVL against similar companies across every metric on this page.
north_east Open comparisonbar_chart Data from SEC EDGAR XBRL filings
Synced 4 days ago 4 years · 4 quarters